Progressive Supranuclear Palsy Atypical Latest Advances

Correction: Revisiting Parkinson's disease definition and classification: insights from two emerging biological frameworks.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: April 06, 2026

Cross-disease genetic and epigenetic architecture of the MOBP locus shows convergence in ALS-PSP.

Journal: bioRxiv : the preprint server for biology

Published: April 03, 2026

Pathology and genetics in a global cohort of Parkinsonian Disorders.

Journal: medRxiv : the preprint server for health sciences

Published: April 03, 2026

A case of progressive supranuclear palsy with progressive non-fluent agrammatic variant primary progressive aphasia who could sing fluently

Journal: Rinsho shinkeigaku = Clinical neurology

Published: March 15, 2026

Metabolomic Cerebrospinal Fluid Biomarkers for the Diagnosis of Atypical Parkinsonian Syndromes.

Journal: International journal of molecular sciences

Published: February 26, 2026

Atypical Parkinsonism as a Manifestation of Central Nervous System Lymphoma.

Journal: Cureus

Published: February 20, 2026

Cholinergic substrates of gait and postural impairments in Progressive Supranuclear Palsy.

Journal: Research square

Published: February 12, 2026

Patient-reported Vision Quality-of-life in Parkinsonian Syndromes and Ataxias and Association with Clinical Oculomotor Findings.

Journal: medRxiv : the preprint server for health sciences

Published: February 12, 2026

Sex differences for clinical presentations and co-pathologies in four-repeat tauopathies.

Journal: Biology of sex differences

Published: February 10, 2026

Current Neuroimaging Modalities to Distinguish Parkinson's Disease from its Mimics: Imaging Features and Implications for Clinical Practice.

Journal: The neuroradiology journal

Published: February 09, 2026

Reply to the Letter to the Editor regarding "Clinical implications of progressive ventilatory impairment in multiple system atrophy and progressive supranuclear palsy".

Journal: Journal of the neurological sciences

Published: February 07, 2026

Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and Neuroinflammation.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

Progressive Supranuclear Palsy Atypical Latest Advances

Find the Latest Research About Progressive Supranuclear Palsy Atypical

Correction: Revisiting Parkinson's disease definition and classification: insights from two emerging biological frameworks.

Correction: Revisiting Parkinson's disease definition and classification: insights from two emerging biological frameworks.

Cross-disease genetic and epigenetic architecture of the MOBP locus shows convergence in ALS-PSP.

Cross-disease genetic and epigenetic architecture of the MOBP locus shows convergence in ALS-PSP.

Pathology and genetics in a global cohort of Parkinsonian Disorders.

Pathology and genetics in a global cohort of Parkinsonian Disorders.

A case of progressive supranuclear palsy with progressive non-fluent agrammatic variant primary progressive aphasia who could sing fluently

A case of progressive supranuclear palsy with progressive non-fluent agrammatic variant primary progressive aphasia who could sing fluently

Metabolomic Cerebrospinal Fluid Biomarkers for the Diagnosis of Atypical Parkinsonian Syndromes.

Metabolomic Cerebrospinal Fluid Biomarkers for the Diagnosis of Atypical Parkinsonian Syndromes.

Atypical Parkinsonism as a Manifestation of Central Nervous System Lymphoma.

Atypical Parkinsonism as a Manifestation of Central Nervous System Lymphoma.

Cholinergic substrates of gait and postural impairments in Progressive Supranuclear Palsy.

Cholinergic substrates of gait and postural impairments in Progressive Supranuclear Palsy.

Patient-reported Vision Quality-of-life in Parkinsonian Syndromes and Ataxias and Association with Clinical Oculomotor Findings.

Patient-reported Vision Quality-of-life in Parkinsonian Syndromes and Ataxias and Association with Clinical Oculomotor Findings.

Sex differences for clinical presentations and co-pathologies in four-repeat tauopathies.

Sex differences for clinical presentations and co-pathologies in four-repeat tauopathies.

Current Neuroimaging Modalities to Distinguish Parkinson's Disease from its Mimics: Imaging Features and Implications for Clinical Practice.

Current Neuroimaging Modalities to Distinguish Parkinson's Disease from its Mimics: Imaging Features and Implications for Clinical Practice.

Reply to the Letter to the Editor regarding "Clinical implications of progressive ventilatory impairment in multiple system atrophy and progressive supranuclear palsy".

Reply to the Letter to the Editor regarding "Clinical implications of progressive ventilatory impairment in multiple system atrophy and progressive supranuclear palsy".

Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and Neuroinflammation.

Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and Neuroinflammation.